The results from numerous studies analysing the immunosuppressive and pro-angiogenic influence of Gal1 on tumour growth, proliferation, and apoptosis have evidently demonstrated the stark possibilities that Gal1 presents as a cancer therapeutic target. The gene discussed is LGALS1; the disease is neoplasm.